Affordable Access

Access to the full text

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

Authors
  • Arai, Masami1
  • Yokoyama, Shiro2
  • Watanabe, Chie3
  • Yoshida, Reiko1
  • Kita, Mizuho1
  • Okawa, Megumi4
  • Sakurai, Akihiro5
  • Sekine, Masayuki6
  • Yotsumoto, Junko7
  • Nomura, Hiroyuki8
  • Akama, Yoshinori9
  • Inuzuka, Mayuko2
  • Nomizu, Tadashi10
  • Enomoto, Takayuki6
  • Nakamura, Seigo2
  • 1 Cancer Institute Hospital of Japanese Foundation for Cancer Research, Clinical Genetic Oncology, Tokyo, Japan , Tokyo (Japan)
  • 2 Showa University, Breast Center, Tokyo, Japan , Tokyo (Japan)
  • 3 Sophia University, Faculty of Human Science, Tokyo, Japan , Tokyo (Japan)
  • 4 St Luke’s International Hospital, Tokyo, Japan , Tokyo (Japan)
  • 5 Sapporo Medical University, Department of Medical Genetics, Hokkaido, Japan , Hokkaido (Japan)
  • 6 Niigata University Graduate School of Medical and Dental Science, Department of Obstetrics and Gynecology, Niigata, Japan , Niigata (Japan)
  • 7 Ochanomizu University, Natural Science Division, Faculty of Core Research, Tokyo, Japan , Tokyo (Japan)
  • 8 Keio University School of Medicine, Department of Obstetrics and Gynecology, Tokyo, Japan , Tokyo (Japan)
  • 9 Hoshi General Hospital, Clinic of Familial Tumor, Fukushima, Japan , Fukushima (Japan)
  • 10 Hoshi General Hospital, Department of Surgery, Fukushima, Japan , Fukushima (Japan)
Type
Published Article
Journal
Journal of Human Genetics
Publisher
Springer Nature
Publication Date
Nov 08, 2017
Volume
63
Issue
4
Pages
447–457
Identifiers
DOI: 10.1038/s10038-017-0355-1
Source
Springer Nature
License
Green

Abstract

The hereditary breast and ovarian cancer (HBOC) registration system of Japan was established by the Japanese HBOC Consortium. The first trial was registered in 2015 in four institutions to which some registration committee members belonged. We analyzed the information of 830 Japanese pedigrees, who underwent BRCA1/2 genetic testing, including mutation carriers with BRCA1 (N = 127) and BRCA2 (N = 115), and their families. The mutation-positive rate was 19.7%. Variants of uncertain significance were found in 6.5% of all individuals subjected to genetic testing for BRCA1/2. Compared to the United States, Japan had a higher mutation-positive rate in most categories, except for the groups with male breast cancer. Among the intrinsic subtypes of BRCA1-associated breast cancers, 75.8% were triple-negative. The incidence rate of contralateral breast cancer in BRCA1/2 mutation carriers was 0.99%/year. Among 240 mutation carriers, 26 and 62 patients underwent risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO), respectively; the respective frequencies of occult cancer were 7.1 and 3.2%. Metachronous breast cancer after RRM or peritoneal cancer after RRSO was not observed during the follow-up period. The nationwide registration system began last year and the system enables follow-up analysis in Japan.

Report this publication

Statistics

Seen <100 times